AFC-HD AMS Life ScienceAFC-HD AMS Life Science Co.,Ltd.2927東証スタンダード食料品FY ending Aug 2025, consolidated, J-GAAP

AFC-HD AMS Life Science FY ending Aug 2019 results

About 92% of AFC-HD AMS Life Science's sales come from Health care, with Medical products making up much of the rest.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Where the money goes

For every ¥100 AFC-HD AMS Life Science sells, how much goes where, and how much is kept.

FY ending Aug 2019

Margin funnel (derived from reported values)Gross margin 27.8% → Operating margin 6.0% → Net margin 4.8%

Revenue by business segment, and the profit each one keeps.

FY ending Aug 2019

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第43期(2022/09/01－2023/08/31)
ID S100SD2P2023-11-28Open
EDINET (FSA Japan)
訂正有価証券報告書－第41期(令和2年9月1日－令和3年8月31日)
ID S100N0TK2021-12-08Open
EDINET (FSA Japan)
有価証券報告書－第40期(令和1年9月1日－令和2年8月31日)
ID S100K8NO2020-11-25Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.